Medscape June 3, 2024
“Does your insurance cover anti-obesity drugs?” Laura Davisson, MD, once again asked the patient before her. She said these cost-of-care conversations are now a daily occurrence.
While glucagon-like peptide 1 (GLP-1) agonist drugs like Ozempic hold tremendous promise in tackling diabetes, obesity, and other disorders, costs remain a significant concern and, for some patients, a roadblock. Physicians must have nuanced discussions with patients about how to afford the high-cost treatments as they increase in popularity, Davisson said.
“We don’t get trained in how the healthcare system works in medical school or residency,” said the internist and director of medical weight management at West Virginia University in Morgantown, West Virginia. “All of a sudden, we’re faced with questions about how patients...
Today's Sponsors
Today's Sponsor